Nicholas Hall’s 32nd European Conference Review

CHC Insight Europe Deputy Editor Nathalie Corbett has filed the following report of the highlights of Nicholas Hall’s 32nd European CHC Conference & CHC Training Academy Workshop, which took place from 4th to 6th May in Athens:

  • Although innovation is key to driving growth, there is too little of it; we have seen few large switches globally and it is difficult to be a switch pioneer.
  • We must aim to bring value to consumers and only innovate where we meet their needs. Success of the past is not a guarantee of success in the future.
  • Being a launch machine is not necessarily the way to grow and new launches do not always equal success; it is just as important to manage the assets we already have for long-term brand sustainability and growth.
  • Self-care can help alleviate the growing strain on healthcare services, but we must work hard to gain the trust of HCPs and convince them of the important role of preventive wellness solutions.
  • We need to move towards sustainable and robust healthcare systems, working collaboratively to enhance their resilience.
  • We live in a time of rapid change, with many forces disrupting the health & wellness landscape and shaping consumer demand; one of the key challenges in today’s industry is adapting to this new reality, which is crucial to keep pace, remain relevant and enable innovation.
  • Health is not a one-size-fits-all concept and it is important to know and understand the varied landscape and identify the ever-changing motivations & drivers of individual groups in order to meet their needs.
  • We need to address consumer health & wellness needs more holistically; personalisation remains a global megatrend and one that will continue to evolve. We are seeing a shift to more personalised and proactive care that empowers consumers to identify their needs, make informed choices and adopt healthier lifestyles.
  • Protection has moved to the fore of consumer consciousness amid the Covid-19 pandemic, with today’s consumer health-oriented, informed, connected, empowered and proactively searching for better health & wellness outcomes.
  • The pandemic has seen an explosion in e-Commerce and accelerated demand for DtC purchases, providing huge opportunities, but bringing with it responsibilities and risks.
  • Systems need to be in place to anticipate these risks, coupled with processes to mitigate them; safeguards, best practices and governance are key. Be mindful of your obligations before charging ahead with innovation.
  • Technology can help us gather and sort a large amount of disparate data, granting us insights to better understand consumer needs, predict consumer choices and enable innovation.
  • It is important to constantly review and respond to data as it changes fast: Gather, Learn and Act.
  • AI is forecast to be the most disruptive technology over the next 50 years, unlocking value of more than US$13tn across all industries. However, while AI can support the work of people, it cannot substitute it, so it is essential to integrate both into business models. Technology should aid innovation but not be the end goal, and consumers must always sit at the centre of strategy. 

Nicholas Hall’s Touchpoints: My colleague Nathalie has written an excellent summary of the Athens meeting, with particular emphasis on the key word in the conference title, “Innovation”. And I wrote last week of the sense of joy among delegates, speakers and staff at being abroad – or just out of the office or home office – in the wide-wide world. I hope that this sentiment will be in evidence at next year’s meeting, which will take place in one of our favourite cities, London.

If you missed the chance to attend our 32nd European CHC Conference & CHC Training Academy Workshop in Athens last week, you can still purchase a recording of the event! View presentations from Nicholas and experts from companies including GSK, Menarini and Teva, who explore what is next for the CHC market landscape across the region. Please contact elizabeth.bernos@NicholasHall.com to purchase your copy.

GSK eyes CBD market with Cann partnership

Cann Group has entered into an exclusive evaluation & option agreement with GSK Consumer Healthcare in relation to the potential commercialisation of Satipharm CBD capsules for OTC (S3, Pharmacist-only) distribution in Australia. GSK also has potential interest in first rights to negotiate exclusivity periods to assess its interest in taking up commercialisation rights in other markets globally. Cann has granted GSK the exclusive right to evaluate Satipharm (excluding Cann’s Rx CBD products) for 60 days after the delivery of Cann’s final clinical study report.

In consideration of this, GSK will pay Cann £100,000 (US$130,437) as a non-refundable payment. Key terms of any definitive sales & marketing agreement will be contingent on factors including the results of the 4-week Phase 3 clinical trial and path to regulatory approval, as well as GSK’s marketing evaluation. Recruitment for the trial, which will examine the efficacy of Satipharm for the short-term treatment of sleep disturbances and quality of life outcomes, is in progress and the results are expected in H2 2022.

As highlighted in our recently published Innovation in CHC report, global launch activity for CBD products has dropped off substantially over the past two years since the pandemic. Regulatory uncertainty also still hovers over the status of CBD in the key US market, another factor in NPD dropping sharply there. In the near future, we expect there to be a greater emphasis on quality over quantity. Further clinical backing for CBD and other cannabinoids – in the way GSK is pursuing with this Cann partnership – will be crucial to this next phase in the maturity of the category.

Source: Nicholas Hall’s CHC New Products Tracker

Nicholas Hall Writes: “This is a very important story. As Peter Crock, the Cann CEO, says: “Cann’s ability to produce a CBD capsule that presents as a regular pharmaceutical and has proven benefits in terms of stability and bioavailability has attracted interest from a number of potential distribution partners. We are delighted to have this opportunity to work with GSK Consumer Healthcare, which would bring industry-leading expertise and market access to our CBD product platform if we enter into a definitive exclusive agreement.”

Alright, it’s not a done deal yet, but there is an expectation that it will be concluded for Australia, and possibly other markets. It is highly significant in many ways:

  1. It’s the first major move since Australia approved CBD for certain OTC indications in February 2021 
  2. With all due deference to Nestlé, it’s the first instance of a major CHC company taking a direct interest in the CBD market
  3. There is some real science involved
  4. The sleep indication will be a sure-fire winner in a category that grew 13.2% in 2021 and still has massive unmet consumer demand

And finally, is it a sign of the greater freedom that the independent Haleon will have to enter “difficult” categories, which might not be possible for an affiliate of Big Pharma? All in all, this is a bold move, and one I hope will succeed.

We are pleased to announce that the latest edition of Innovation in CHC from CHC New Products Tracker is now published! This report showcases 100 major innovations from 2021, profiles best-in-class brands and highlights key ingredient and delivery format trends. To order your copy now, or for more information, please contact melissa.lee@NicholasHall.com.

Prebiotics on cusp of exponential growth


According to prebiotics developer, Swiss-based Clasado, the category has “exponential” growth potential, with increasing consumer awareness and an upswing in demand from key players. CEO Per Rehne said: “Because the prebiotics market has gathered pace over a relatively short space of time, it’s easy to forget that the isolated ingredients are still relatively new compared to many of today’s nutrition technologies. Global Market Insights predicts a very solid 8.5% global CAGR until 2024, but it is likely to surpass this … [in a] perfect example of the ‘right technology, connecting with the right market, at the right time’.” He added: “Real market appetite [is] reflected in new product innovation from some of the biggest international brands”.

Clasado is working on a “major project” with P&G, which will see galactooligosaccharide prebiotic ingredient Bimuno  “feature heavily in a novel gummy designed to make a real difference to the consumer.” Rehne concluded: “It’s an exciting time for brand owners and formulators. We’re only just scratching the surface of what prebiotics are capable of in terms of capturing consumer attention and unlocking fundamentally better gut health.”

Coinciding with April’s IBS Awareness Month, i-Health / DSM has launched Culturelle IBS Complete Support in the USA for the dietary management of IBS. The first product from the brand that does not contain probiotics, the medical food – to be used under medical supervision and direction – is powered by HMO (human milk oligosaccharide) bioactive prebiotics, natural digestive nutrients that promote the growth of good gut bacteria. It claims to be able to reduce the severity of symptoms such as stomach pain, bloating, constipation and diarrhoea by 60% and cut days with symptoms by 50%. In tandem, the “Take Back Your Days” campaign offers consumers the chance to win US$100 to spend doing something they enjoy with their reclaimed time. The first 1,000 entrants will receive a box of Culturelle IBS Complete Support, which is available now at a number of retailers with a suggested retail price starting at US$29.98 for a box of 28 single serve packets. The recommended dose for adults and children aged 12+ years is one packet once daily, mixed in liquids or food.

Comment from Dave Redford, Managing Editor, CHC New Products Tracker: This new Culturelle product is a unique proposition in several ways: Formulation (first Culturelle product with no probiotics, just prebiotics); Regulatory status (first Culturelle product to be registered as a medical food); and Positioning (first Culturelle product for IBS). Still by far the No.1 US probiotics & prebiotics brand with sales of over US$150mn, Culturelle has however seen growth slow in the past two years in line with the category overall, as competition intensifies and the market matures. With a claim to offer “more symptom-free days” to IBS sufferers, backed by clinical research, i-Health clearly sees Culturelle IBS Complete Support as offering a new avenue for growth.

Review the best in class innovations among GIs and probiotics & prebiotics from the past year in our recently published Innovation in CHC 2021 report from CHC New Products Tracker. Showcasing 110 of the latest innovations across CHC categories, with a look at trends in delivery format and ingredients, as well as profiling innovation by the leading players, for more information, or to order your copy, please contact melissa.lee@NicholasHall.com

CCA down, but mental wellness products boom

Global CHC market sales in bricks & mortar outlets totalled US$150bn in 2020, with growth decelerating to 3.3%. Categories that were hardest hit by the slowdown were concentrated among CCA (notably cough and sore throat remedies) and Dermatologicals (such as lip care, cold sore and head lice treatments), as a result of social distancing guidelines. However, there were some notable sales successes in 2020, including sedatives & sleep aids and herbal memory & brain health supplements.

As we wrote in the latest issue of CHC.NewDirections: “Sleep quality has deteriorated as the Covid-19 pandemic has progressed, according to the ongoing University College London Covid-19 Social Study. Of the more than 70,000 participants, 12.7% reported “very good” sleep quality in March 2020 vs only 7.7% in March 2021. The number of people who said their sleep quality was “very poor” increased from 5.4% (Autumn 2020) to 10.1% at the start of the New Year.”

CIMA Market Analyst, Sacha Hawker, notes that this increase in sleep disturbance has been accompanied by a rise in sleep-related apps and devices in recent years, creating even more crossover between technology and consumer healthcare. And globally, there have been more than 160 new products with a mental wellness positioning since the pandemic began in December 2019 (Source: Nicholas Hall’s CHC New Products Tracker). With lockdown measures still in place alongside other stress factors, we expect this trend to continue.

Four notable 2020 sleep device launches from our Innovation in CHC report:
Withings Analyzer (Europe), SleepCheck (Australia), Sunrise (UK) and CoolDrift Versa (USA)

Commenting on the DB6 results, Nicholas Hall said: So there it is! Finally, the 2020 growth rate was somewhat lower than expected at 5% (all channels of distribution), more or less in line with the five years before the Covid outbreak. But within the market there has been radical change, and the stable overall growth rate cannot disguise the weakness of the cough & cold market – much worse than expected – and indeed of the whole retail sector. At the moment we are working on the short-term and long-term forecasts for the new edition of DB6, and there are puzzled frowns and long faces among the forecasting team.

So where do we look for rays of sunshine? As my colleague Celine Waller writes, anything connected with immunity and disinfection and e-Commerce is having a fine time, and the expectation is that this boom will carry over for two or three more years. And she points to sedatives & sleep aids among the rock stars with a 13% growth rate. This ties in perfectly with earlier predictions made during a webinar given by Jennifer Cooper and I a month ago. If you haven’t listened to the recording of that webinar, I strongly advise you to do so (link here).

Only two weeks to go until our European e-Conference 2021! Register now to explore e-Commerce and other major trends impacting CHC on 28-29 April with Nicholas Hall and a panel of industry experts.
For a look at the full agenda, please click here
To book your place at our European e-Conference, or to find out more about our other webinars, please contact Elizabeth.Bernos@NicholasHall.com 

Nasal sanitisers niche opens up post-Covid

One of the fast-emerging OTC niches in the CCA category is oral & nasal sanitisers, with several notable innovations in 2020 and 2021, including two more nasal sanitiser launches announced recently.

Australian-based Starpharma’s Viraleze nasal spray will become available online in the UK this week ahead of a retail rollout in April 2021, under an exclusive sales & distribution agreement with the retail chain, LloydsPharmacy (McKesson). This will be the product’s first appearance in Europe, although a regional launch is expected soon following its registration in the European Economic Area in February.

Comment from CHC Insight Managing Editor, Chris Allan: Viraleze contains the same antiviral ingredient (SPL7013 / astodrimer sodium) that features in Starpharma’s VivaGel products. Its powerful claim to deactivate “>99.9% of Sars-CoV-2 within one minute” is likely to attract wider media interest given the continuing national focus on the pandemic, and LloydsPharmacy has committed to “significant” marketing investment.

Separately, in Israel, SaNOtize has received interim approval to sell its nitric oxide nasal spray (NONS) in pharmacies. NONS protects users from viruses that enter the body through the upper nasal pathways. Local manufacturing under the brand name Enovid has begun in partnership with Nextar Chempharma Solutions and the spray is expected to appear on pharmacy shelves by the summer.

Meanwhile, in New Zealand the Ministry of Health denied claims by the Canadian-based biotech company that Enovid had been cleared for immediate OTC sale. Newshub quotes a MoH spokesperson: “Based on the therapeutic claims made for the product, its claimed mode of action and the nitric oxide ingredient, Enovid nasal spray would be a prescription medicine under New Zealand law (Medicines Act 1981) … Medsafe has received no applications for approval of this product for sale, supply or use in New Zealand.”

Comment: SaNOtize and Ashford & St Peter’s Hospitals NHS Foundation Trust in the UK recently announced results of clinical trials indicating that NONS represents a safe and effective antiviral treatment that could prevent the transmission of Covid-19, shorten its course and reduce the severity of symptoms and damage in those already infected.

Oral & nasal sanitisers is one of the delivery formats trends covered in our new Innovation in CHC 2021: NPD & Launch Activity under the Spotlight report. Seize the last chance to save GB£1,350 when you pre-order this forthcoming report before 31st March. To review the table of contents or pre-order your copy, please contact melissa.lee@NicholasHall.com

Sexual health OTC revolution

Building on the news covered in last week’s blog that Sanofi is planning to implement the US Rx-to-OTC switch of erectile dysfunction treatment Cialis by end-2024, this week we look at another major development in the OTC sexual health & fertility category – the announcement by the UK’s MHRA that it has launched a public consultation on the reclassification of two progestogen-only contraceptive pills containing desogestrel, marking the first time the agency has considered such a change.

MHRA is asking the public and stakeholders for their views on whether two continuous-use oral contraceptives – HRA Pharma’s Hana and Maxwellia’s Lovima, both as 75mcg film-coated tablets in 28-count packs – should become pharmacy medicines and available OTC, without a medical prescription (although, in parallel, desogestrel 75mcg will also remain available on prescription, with women potentially able to switch between prescription or pharmacy supply at different times). The agency notes that if the products are reclassified, pharmacists will have access to training materials and a checklist to help them to identify women who can receive the two medicines safely. Two separate consultations are open until 5th March (Hana link; Lovima link).

Following the switch of Adamed’s Maxon Forte (sildenafil 50mg) in Poland in early 2020, the rollout of OTC Viagra (Viatris) to Norway and Ireland in 2020, plus the EU centralised Rx-to-OTC switch of Fortacin (Recordati for Plethora Solutions) for premature ejaculation – formulated with lidocaine 150mg + prilocaine 50mg – in September 2020, the past year has seen a rapid expansion in the availability of OTC sexual health & fertility medicines. With OTC ED on the near horizon in the US market, the UK approval of the daily contraceptive pill as an OTC medicine could lead to a wave of similar approvals worldwide, and inject substantial growth into the global CHC market over the coming years.

CHC.NewDirections Consulting Editor, Nina Stimson adds: This really is an exciting proposal – not only a first for the UK, but also the first significant bid to offer oral contraceptives without prescription outside the Asia Pacific region – China and South East Asian markets lead the way, although sales in most markets are relatively small. If the proposal is approved, will UK pharmacists actively support the switch and help build OTC supply (and will the pharmacy protocol be sufficiently user-friendly not to push women back to the doctor)? And will any price differential between Rx or OTC supply be a factor? Not all ambitious switches in the UK have succeeded in the past, but we have high hopes for this one. Time will tell …

You can save up to GB£1,350 when you pre-order our forthcoming report from CHC New Products Tracker, Innovation in CHC: 2020’s NPD & Launch activity under the spotlight before 31st March! As well as looking in more depth at the latest OTC sexual health & fertility developments, the report also showcases the top 100 innovations in 2020 and features major ingredient trends, delivery format trends and much more. For more information, or to pre-order your copy, please contact melissa.lee@NicholasHall.com.

Sanofi CHC on track to be standalone unit by end-2022

At Sanofi’s Capital Markets Day 2021, the company’s Head of Consumer Healthcare, Julie Van Ongevalle, shared her vision for the business: “With the ongoing implementation of our fully integrated standalone model, we look forward to being more agile and reducing the complexity of our portfolio to drive growth with our consumer-centric, data-driven marketing approach.” The aim is to divest around 150 brands (from the current 250) in the next two years to focus on “priority categories”, such as allergy, body pain, general pain and mental wellness – particularly sleep aids – via a “granular approach”.

Rx-to-OTC switch has already been a key factor in driving growth in one of Sanofi’s priority categories, allergy remedies, thanks to the successful global OTC rollout of Allegra (first available in the USA in 2011) and launch of Xyzal Allergy 24HR (USA, 2017). Josephine Fubara, Chief Science Officer at Sanofi CHC, noted that Sanofi continues to make progress in bringing two potential OTC switches to the market in the coming years, erectile dysfunction treatment Cialis and flu antiviral Tamiflu, presenting a blockbuster opportunity with a combined sales potential of €1bn in the US market alone.

Source: Sanofi Capital Markets Day 2021 presentation

Sanofi also stated that it is on track with its plans to be a standalone CHC business by end-2022. The company said that the overall planning for the transition was complete, and that the majority of its standalone CHC legal entities would be operational by end-2021. Among the benefits that Sanofi believes this transition will bring include the agility to reignite its innovation engine and reduce time-to-market by around 20%.

Looking ahead, Sanofi is targeting above average market growth, driven by its focus on priority categories and Rx-to-OTC switch, with a view to becoming the best-in-market CHC performer by 2024-25. Supporting this objective will be a focus on consumer insights, an emphasis on e-Commerce and digital channels and the operational independence provided by Sanofi’s standalone model.

Save up to GB£1,350 when you pre-order our forthcoming report from CHC New Products Tracker, Innovation in CHC: 2020’s NPD & Launch activity under the spotlight before 31 March. The report showcases the Top 100 innovations in 2020 and features major ingredient trends, delivery format trends, and much more. For further details, or to pre-order your copy, please contact melissa.lee@NicholasHall.com.

Innovation: CES 2021 Health & Wellness Roundup

As our infographic this week indicates, health & wellness led the way in terms of high-quality innovation at this year’s CES (Consumer Electronics Show). Here, we highlight some of the new health & wellness products that were rewarded by judges for the key criteria of excellence in engineering, aesthetics and design, uniqueness, and the innovation they bring to the consumer market.

The winner of the Best of Innovation award in the health & wellness category was Epsy Health, a leading digital health platform for the management of epilepsy that “empowers patients, caregivers and healthcare professionals”. The Epsy app is free to download on both Apple and Android platforms, currently in the USA only, and helps in managing epilepsy by “creating a data rich diary to track seizures, medication compliance and triggers”.

The other level of recognition in each CES category is “Honorees”, i.e. products that score above the threshold in terms of innovation criteria for any given category, and there were several digital healthcare tools here, including Algocare, an IoT (Internet of Things) solution that provides personalised nutrition management at home and at work. Algocare Labs, based in South Korea, claims that the health questionnaires on the Algocare app and its unique algorithm, which analyses thousands of scientific journals, combine to deliver a tailored VMS mix to be dispensed via Algocare’s innovative device. Another CES Honoree was Oova, a high-tech home diagnostic fertility test, which measures luteinising hormone and progesterone in the urine, thanks to its cutting-edge test pads and supporting smartphone app.

Other notable consumer health & wellness innovations at CES 2021 included Flō, a handheld device for managing allergic rhinitis (or hayfever). When placed in the nose and activated, the company says the product projects lights to trigger reactions in the body which limit uncomfortable allergy symptoms. Marketer Fluo Health said it is seeking OTC approval from the FDA, and expects the device to be available to consumers later this year. Another medical device of note was Temp Pal, a smart thermometer from Taiwan-based iWEECARE, which is designed to be placed under the armpit of small children and transmits its readings wirelessly for remote monitoring – according to the company, it measures a child’s temperature within an accuracy of 0.05 degrees Celsius.

Explore the latest cutting-edge consumer healthcare devices, as well as major delivery format and ingredient trends, in our upcoming report from Nicholas Hall’s CHC New Products Tracker, Innovation in CHC: 2020’s NPD & Launch activity under the spotlight! Pre-order your copy before 31 March to save with a generous pre-publication discount. To find out more, please contact melissa.lee@NicholasHall.com.

Innovation powers Genomma OTC growth in LatAm, USA

CHCINACTION

Ranking among the Top 50 globally and the No.5 CHC marketer in Latin America, Genomma continues to produce double-digit OTC growth. In its recently published Q2 2020 results, Genomma announced a 10.9% rise in net revenue in Q2 to Ps3.6bn (US$160mn). Adjusted EBITDA grew by 13.1% to Ps754.9mn (US$34mn; 20.8% margin). Mexican sales reached Ps1.5bn (US$67mn; +5.0%), while revenue from LatAm markets was up 8.8% to Ps1.6bn (US$71mn). Reversing the downward trend of recent quarters, sales from Genomma’s US operation grew by 47.8% to Ps478.4mn (US$21mn), attributed to a renewed focus on innovation, POS (point-of-sale) presence and A+P.

Overall, Genomma generates 54% of its revenue from OTC products, with personal care accounting for the remainder. Genomma now has a presence in 18 markets, and international expansion has fuelled the fast quarterly growth in its OTC portfolio (+32.2% in Q2 2020 vs Q2 2019), which offset a 6.5% decline its personal care sales. Mexico accounted for 38% of Genomma’s OTC turnover in Q2 2020, and quarterly sales in its home market fell 2.7%, however this was more than offset by 49.8% growth in LatAm sales (excluding Mexico), which accounted for 42% of its OTC portfolio in Q2, and 128.5% growth in USA sales, which now claim a 20% OTC share.

Screen Shot 2020-07-27 at 10.03.10.png

Source: Genomma’s Q2 2020 Earnings Release

CHC Insight Latin America Assistant Editor, Jen Jones, commented: “Innovation was the buzzword in Genomma’s Q2 statement to investors. In Mexico, new categories include infant nutrition, sanitisers and shaving products, while in Brazil Genomma recently introduced the region’s first at-home HIV test kit. CCA was central to NPD in LatAm, including launches under the Next banner in Brazil, Argentina and Colombia, as well as the rollout of Tukol cough remedy to new regional markets.”

According to our CHC New Products Tracker service, after a quiet year in 2017, Genomma significantly ramped up NPD activity in 2018 and 2019, and this investment is now being reflected in strong organic OTC growth. While Brazil and Argentina were the main sources of launch activity in that period, the US market has also been a growing focus, with line extensions to skin care brands Lagicam (antifungal), Asepxia (acne remedy) and Cicatricure (aesthetic treatment), as well as additions to the Next systemic cold & flu range (Daytime Relief and Nighttime Relief).

Thousands of innovations are launched every year in the global consumer healthcare market, but relatively few offer notable new benefits for consumers in terms of delivery format or formulation. Which new products are breaking through and offering a unique proposition? Where will new product development take the CHC market in future? Contact Melissa Lee (melissa.lee@nicholashall.com) today to pick up your copy of the Innovation in CHC report.

Immunity sales & NPD activity on the rise

CHCINACTION

One of the newer CHC subcategories that appeared in the Top 10 biggest contributors to global consumer healthcare growth in the MAT Q1 2010 period was immune supplements, with the subcategory producing a 28.5% global upturn in the year to end-March 2020. Along with vitamin C products, probiotics and multivitamins, immune supplements were among several major VMS contributors to growth in the first quarter.

For 2019, our CHC New Products Tracker service recorded 95 new product developments in the herbal & natural immune stimulants subcategory, making it the 14th most active subcategory overall in the consumer healthcare market. So far in 2020, immune supplements are already in the Top 10 most active subcategories – a sign of the rapid increase in new product development in response to the Covid-19 pandemic – and we fully expect this growth in NPD activity to accelerate over the remainder of the year.

Screen Shot 2020-07-13 at 12.50.19.png

There has been a wide array of immunity NPD activity across all regions, notably Europe, North America and Asia-Pacific. In certain markets, such as India and China, there is also likely to be a rise in sales of country-specific natural remedies (Ayurvedic medicine and TCM) positioned for immunity support, though marketers will have to be wary of government clampdowns on products that are claimed to prevent or cure Covid-19.

Notable immunity supplement launches in the USA so far in 2020 include GSK’s Emergen-C Turmeric & Ginger and Emergen-C Elderberry, available in fizzy drink mixes, and RB’s Airborne Immune + Natural Energy Ready To Drink Shot. In Europe, Neuraxpharm unveiled Preventan Clasic in Spain and Italy, while Sambcol Immuno Forte and Sambucol Kids + Vitamin C were rolled out in Germany. As for Asia-Pacific, Grandma’s Kadha effervescent tablets were launched in India and Sanofi’s Cenovis line was relaunched in Australia.

Thousands of innovations are launched every year in the global consumer healthcare market, but relatively few offer notable new benefits for consumers in terms of delivery format or formulation. Which new products are breaking through and offering a unique proposition? Where will new product development take the CHC market in future? Contact Melissa Lee (melissa.lee@nicholashall.com) today to pick up your copy of the Innovation in CHC report.